Identification of Genetic Determinants for Treatment Resistance/Sensitivity and/or Toxicity in Adjuvant Setting for HER2 Positive Breast Cancer
Recruiting
Observational Study
HER2-positive Breast Cancer
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Female
- Study type
- Observational
- Participants needed
- 9,000 (estimated)
- Sponsor
- Centre Paul Strauss · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This is a multicenter, non-randomized, prospective cohort study. The purpose of the study is to identify constitutional genetic factors associated with histological response, resistance or sensibility to treatment in human epidermal growth factor receptor 2 (HER2)-positive breast cancer. 9000 patients will be enrolled in this study. Blood samples will be collected after informed consent and inclus…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
For inclusion in the study, patients must be affiliated to the national or local social security, and must meet all the following criteria:
Inclusion Criteria:
* Age ≥ 18 years
* Histological diagnosis of breast adenocarcinoma. Non-metastatic and operable.
* Current or prior treatment with one the…
Contacts